Glenmark Pharmaceuticals Inc., USA Launches Lacosamide Oral Solution, 10 mg/mL

Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the launch of Lacosamide Oral Solution, 10 mg/mL. This product is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat®? Oral Solution, 10 mg/mL of UCB, Inc. The Vimpat® Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million*. Glenmark's Lacosamide Oral Solution is part of the company's commitment to provide quality and affordable alternatives for patients. Glenmark's current portfolio includes 201 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the U.S. FDA. The company is also exploring external development partnerships to enhance and accelerate the growth of its existing pipeline and portfolio.